Can aripiprazole cause hyponatremia (low serum sodium)?

Can Aripiprazole Cause Hyponatremia?

Yes, aripiprazole can cause hyponatremia, though it appears to carry a lower risk compared to other antipsychotics like olanzapine. While the FDA label does not explicitly list hyponatremia as a common adverse effect 1, multiple case reports and recent comparative studies demonstrate this association exists and can be clinically significant.

Evidence Quality and Strength

The evidence comes from three sources with varying strength:

• FDA labeling 1 does not specifically mention hyponatremia as a recognized adverse effect, which suggests it is uncommon in clinical trials
• Recent comparative research 2 from 2026 analyzing 961,010 patients found aripiprazole had a 52% lower risk of hyponatremia compared to olanzapine (adjusted HR 0.52,95% CI 0.35-0.76)
• Multiple case reports 3, 4, 5, 6 document SIADH (syndrome of inappropriate antidiuretic hormone secretion) occurring with aripiprazole, including rechallenge cases that strongly suggest causality

Clinical Presentation and Mechanism

When aripiprazole-induced hyponatremia occurs, it typically manifests as:

• Timing: Can develop rapidly (within 3 days) 5 or after dose increases 4
• Mechanism: SIADH with euvolemic hypoosmolar hyponatremia 4, 6
• Laboratory findings: Low serum sodium (<130 mEq/L), low serum osmolality, inappropriately elevated urine osmolality (>500 mOsm/kg), and elevated urine sodium (>20-40 mEq/L) 7, 8
• Symptoms: Dizziness, headache, nausea, vomiting, confusion, and in severe cases (<120 mEq/L), seizures or altered consciousness 8, 4

Risk Assessment and Monitoring

Monitor sodium levels in these high-risk scenarios:

• Within the first week after starting aripiprazole or increasing the dose
• Patients with pre-existing risk factors: elderly, concurrent diuretic use, baseline low sodium, SSRI/SNRI co-administration 7, 9, history of SIADH
• Any patient developing new confusion, dizziness, or gastrointestinal symptoms

The comparative study 2 suggests aripiprazole may actually be a safer choice for patients at high risk of hyponatremia compared to other second-generation antipsychotics, particularly olanzapine.

Management Algorithm

If hyponatremia develops:

1. Confirm SIADH diagnosis by excluding other causes 7, 8:

   • Rule out diuretic use, hypothyroidism, adrenal insufficiency
   • Check volume status (should be euvolemic)
   • Verify lab criteria: serum Na <130 mEq/L, serum osmolality <275 mOsm/kg, urine osmolality >300 mOsm/kg, urine Na >40 mEq/L

2. Severity-based intervention:

   • Mild (Na 125-130 mEq/L, asymptomatic): Fluid restriction to 1-1.5 L/day 7, 10, 11
   • Moderate (Na 120-125 mEq/L): Discontinue aripiprazole, fluid restriction, consider hospitalization 10
   • Severe (Na <120 mEq/L or symptomatic): Immediate hospitalization, discontinue aripiprazole, hypertonic 3% saline if life-threatening symptoms (seizures, coma), correct no faster than 8-10 mEq/L per day to avoid osmotic demyelination 8, 12, 11

3. Psychiatric medication adjustment:

   • Consider switching to an antipsychotic with lower SIADH risk if aripiprazole must be discontinued 13
   • Do NOT rechallenge with aripiprazole—case reports show recurrence upon rechallenge 3, 4

Critical Pitfalls to Avoid

• Do not assume aripiprazole is completely safe regarding hyponatremia just because it's not prominently listed in FDA labeling—case reports prove otherwise
• Do not use fluid restriction alone for moderate-to-severe hyponatremia; it is rarely effective and delays definitive management 12, 11
• Do not correct sodium too rapidly (>8-10 mEq/L/day) as this risks osmotic demyelination syndrome, especially in chronic hyponatremia 12, 11
• Do not overlook medication interactions: SSRIs, SNRIs, diuretics, NSAIDs, and chemotherapy agents all increase SIADH risk when combined with antipsychotics 7

Bottom Line for Clinical Practice

While aripiprazole appears to have a lower risk profile for hyponatremia compared to other antipsychotics 2, it can still cause clinically significant SIADH requiring hospitalization and medication discontinuation 3, 4, 5, 6. Check baseline sodium before starting aripiprazole in high-risk patients, monitor within the first week of initiation or dose escalation, and maintain a high index of suspicion for new neurological or gastrointestinal symptoms. If SIADH develops, discontinue aripiprazole permanently and do not rechallenge.